Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 14/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 12/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.90 |
| ▸ | PAK4 | O96013 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | LTK | P29376 | 2/20 | 0.90 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.90 |
| ▸ | CLK2 | P49760 | 2/20 | 0.90 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.90 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.90 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.90 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.90 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.90 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.90 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.90 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.90 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL31073616 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL29677819 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL1369365 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL1371422 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Phosphoric Acid SCHEMBL20474415 | 0.96 | JAK2 (0.93) | JAK2JAK1JAK3TYK2DAPK3 | |
| Phosphoric Acid SCHEMBL3001694 | 0.96 | JAK2 (0.93) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL101279 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL31247553 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL29677353 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL171319 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3131 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137695-A1 | COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | INCYTE CORP (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099445-A1 | RUXOLITINIB PHOSPHATE CONTROL RELEASE FORMULATION | SYNTHON B.V (NL) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727526-A1 | TOPICAL SKIN FORMULATIONS OF A PHARMACEUTICALLY ACCEPTABLE SALT OF RUXOLITINIB | Incyte Corporation (US) | 2026-04-22 | — | — | EP | claimed |
| US-12589096-B2 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | INCYTE CORPORATION (US) | 2026-03-31 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3972982-A1 | BORONIC ESTER PRODRUGS AND USES THEREOF | Massachusetts Institute of Technology (US) | 2022-03-30 | — | — | EP | claimed |
| WO-2022061351-A1 | TOPICAL TREATMENT OF VITILIGO | INCYTE CORPORATION (US) | 2022-03-24 | — | — | WO | claimed |
| US-11278541-B2 | Low dose combination therapy for treatment of myeloproliferative neoplasms | INCYTE CORPORATION (US) | 2022-03-22 | — | — | US | claimed |
| US-11266743-B2 | Peptide compositions and methods of use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-03-08 | — | — | US | claimed |
| WO-2022040180-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220056035-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2022-02-24 | — | — | US | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3949953-A1 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB | Incyte Holdings Corporation (US) | 2022-02-09 | — | — | EP | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |